上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2023 , Vol. 43 >Issue 12: 1554 - 1561

DOI: https://doi.org/10.3969/j.issn.1674-8115.2023.12.011

综述

腹腔灌洗液循环肿瘤DNA在预测胃肠道恶性肿瘤腹膜转移中应用的研究进展

  • 白龙 ,
  • 夏翔 ,
  • 曹晖 ,
  • 张子臻
展开
  • 上海交通大学医学院附属仁济医院胃肠外科，上海 200127
白 龙（2000—），女，硕士生；电子信箱：bailong001001@163.com。
张子臻，电子信箱：zhangzizhen@renji.com。

收稿日期: 2023-07-23

  录用日期: 2023-10-27

  网络出版日期: 2024-02-01

基金资助

国家自然科学基金项目(81972206);上海市“医苑新星”青年医学人才培养资助计划(2022-65);上海市卫生健康委员会卫生行业临床研究专项(202140458);上海市自然科学基金项目(22ZR1438800);上海交通大学医学院附属仁济医院培育基金(RJTJ22-MS-025)

收起

Progress in application of peritoneal lavage fluid circulating tumor DNA to predicting peritoneal metastasis of gastrointestinal cancer

  • Long BAI ,
  • Xiang XIA ,
  • Hui CAO ,
  • Zizhen ZHANG
Expand
  • Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
ZHANG Zizhen, E-mail: zhangzizhen@renji.com.

Received date: 2023-07-23

  Accepted date: 2023-10-27

  Online published: 2024-02-01

Supported by

National Natural Science Foundation of China(81972206);Shanghai "Medical Garden Rising Star" Young Medical Talent Training Grant Program(2022-65);Health Industry Clinical Research Project of Shanghai Municipal Health Commission(202140458);Shanghai Natural Science Foundation(22ZR1438800);Cultivation Fund of Renji Hospital, Shanghai Jiao Tong University School of Medicine(RJTJ22-MS-025)

Fold

摘要

腹膜转移是胃肠道恶性肿瘤患者死亡的重要原因之一，也是临床诊治的难点。如何在具有高危因素的患者中预测腹膜转移的发生，将诊治关口前移至腹膜转移发生之前，提高患者的生存获益，是目前临床工作中尚未解决的问题。在细胞学检查阳性率较低、隐匿型腹膜转移诊断困难的情况下，能够早期诊断腹膜转移的分子标志物与检测技术亟待验证。腹腔灌洗液具有较少的白细胞来源的无细胞DNA干扰，相对循环肿瘤DNA（circulating tumor DNA，ctDNA）浓度更高；并且，与原发病灶或潜在腹膜转移灶的直接接触，使其在胃肠道肿瘤的预测中有独特的优势。目前，腹腔灌洗液中ctDNA的检测方式有数字PCR、基于表观遗传的分析方式以及二代测序等。随着技术的迭代，应用二代测序及个性化定制面板进行ctDNA检测，不仅在预测术后腹膜转移方面展现出了极大潜力，更是对腹膜转移进行预防性升阶治疗设想的推动力量。该文对腹腔灌洗液ctDNA在预测胃肠道恶性肿瘤腹膜转移中的应用进行综述。

关键词： 胃肠道恶性肿瘤; 腹膜转移; 腹腔灌洗液; 循环肿瘤DNA

本文引用格式

白龙 , 夏翔 , 曹晖 , 张子臻 . 腹腔灌洗液循环肿瘤DNA在预测胃肠道恶性肿瘤腹膜转移中应用的研究进展[J]. 上海交通大学学报（医学版）, 2023 , 43(12) : 1554 -1561 . DOI: 10.3969/j.issn.1674-8115.2023.12.011

Abstract

Peritoneal metastasis is one of the important causes of death in patients with gastrointestinal cancer and is also a difficult point in clinical diagnosis and treatment. How to predict the occurrence of peritoneal metastasis in patients with high-risk factors, advance the threshold of diagnosis and treatment before the occurrence of peritoneal metastasis, and improve the survival benefit of patients is an unsolved problem in clinical work. In the case of low positive rate of cytology and difficulty in diagnosing occult peritoneal metastasis, new molecular markers and detection techniques for early diagnosis of peritoneal metastasis need to be verified. Peritoneal lavage fluid has the characteristics of less leukocyte-derived cell-free DNA interference, higher concentration of circulating tumor DNA (ctDNA), and direct contact with the primary lesion or potential peritoneal metastasis at physical distance, making it a unique advantage in gastrointestinal cancer. At present, the detection methods of ctDNA in peritoneal lavage fluid include digital PCR, epigenetic-based analysis, and next-generation sequencing. With the iteration of technology, the application of next-generation sequencing and personalized panels to ctDNA detection has not only shown great potential in predicting postoperative peritoneal metastasis, but also promoted the idea of preventive escalation treatment of peritoneal metastasis. This article reviews the current application of ctDNA to peritoneal lavage fluid in predicting peritoneal metastasis of gastrointestinal cancer.

Key words： gastrointestinal cancer; peritoneal metastasis; peritoneal lavage fluid; circulating tumor DNA

参考文献

1 SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2 LEI Z, WANG J, LI Z, et al. Hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: a multicenter propensity score-matched cohort study[J]. Chin J Cancer Res, 2020, 32(6): 794-803.
3 YONEMURA Y, BANDOU E, KAWAMURA T, et al. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer[J]. Eur J Surg Oncol, 2006, 32(6): 602-606.
4 FRANKO J, SHI Q, GOLDMAN C D, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase Ⅲ trials N9741 and N9841[J]. J Clin Oncol, 2012, 30(3): 263-267.
5 MO S, CAI G. Multidisciplinary treatment for colorectal peritoneal metastases: review of the literature[J]. Gastroenterol Res Pract, 2016, 2016: 1516259.
6 SáNCHEZ-HIDALGO J M, RODRíGUEZ-ORTIZ L, ARJONA-SáNCHEZ á, et al. Colorectal peritoneal metastases: optimal management review[J]. World J Gastroenterol, 2019, 25(27): 3484-3502.
7 KOEMANS W J, LURVINK R J, GROOTSCHOLTEN C, et al. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort[J]. Gastric Cancer, 2021, 24(4): 800-809.
8 BADGWELL B, BLUM M, DAS P, et al. Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma[J]. Ann Surg Oncol, 2017, 24(11): 3338-3344.
9 中国抗癌协会胃癌专业委员会. 胃癌腹膜转移防治中国专家共识[J]. 中华胃肠外科杂志, 2017, 20(5): 481-490.
9 Gastric Cancer Professional Committee. Chinese expert consensus on prevention and treatment of gastric cancer peritoneal metastasis[J]. Chinese Journal of Gastrointestinal Surgery, 2017, 20(5): 481-490.
10 YANG H K, JI J, HAN S U, et al. Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(2): 120-127.
11 DESIDERIO J, CHAO J, MELSTROM L, et al. The 30-year experience-a meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer[J]. Eur J Cancer, 2017, 79: 1-14.
12 徐岩, 王振宁. 胃癌腹膜转移的临床治疗进展与未来展望[J]. 中华胃肠外科杂志, 2023, 26(5): 414-418.
12 XU Y, WANG Z N. Recent progress and future prospects of treatment for peritoneal metastasis in gastric cancer[J].Chinese Journal of Gastrointestinal Surgery, 2023, 26(5): 414-418.
13 KANDA M, KODERA Y. Molecular mechanisms of peritoneal dissemination in gastric cancer[J]. World J Gastroenterol, 2016, 22(30): 6829-6840.
14 Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition)[J]. Gastric Cancer, 2021, 24(1): 1-21.
15 AMIN M B, EDGE S B, GREENE F L, et al. AJCC Cancer Staging Manual[M]. 8th ed. New York: Springer, 2017.
16 KO?OMA?SKA M M, G?USZEK S. Free cancer cells in gastric cancer: methods of detection, clinical and prognostic importance (meta-analysis)[J]. Contemp Oncol(Pozn), 2020, 24(1):67-74.
17 MATSUI S, FUKUNAGA Y, SUGIYAMA Y, et al. Incidence and prognostic value of lavage cytology in colorectal cancer[J]. Dis Colon Rectum, 2022, 65(7): 894-900.
18 GOMEZ-ARTEAGA A, GUZMAN M L. Minimal residual disease in acute myeloid leukemia[J]. Adv Exp Med Biol, 2018, 1100: 111-125.
19 PANTEL K, ALIX-PANABIèRES C. Liquid biopsy and minimal residual disease: latest advances and implications for cure[J]. Nat Rev Clin Oncol, 2019, 16(7): 409-424.
20 THIERRY A R, EL MESSAOUDI S, GAHAN P B, et al. Origins, structures, and functions of circulating DNA in oncology[J]. Cancer Metastasis Rev, 2016, 35(3): 347-376.
21 HABER D A, VELCULESCU V E. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA[J]. Cancer Discov, 2014, 4(6): 650-661.
22 HEITZER E, HAQUE I S, ROBERTS C E S, et al. Current and future perspectives of liquid biopsies in genomics-driven oncology[J]. Nat Rev Genet, 2019, 20(2): 71-88.
23 PENG Y, MEI W, MA K, et al. Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives[J]. Front Oncol, 2021, 11: 763790.
24 CHIN R I, CHEN K, USMANI A, et al. Detection of solid tumor molecular residual disease (MRD) using circulating tumor DNA (ctDNA)[J]. Mol Diagn Ther, 2019, 23(3): 311-331.
25 YAO W, MEI C, NAN X, et al. Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: a qualitative study[J]. Gene, 2016, 590(1): 142-148.
26 LIU M C, OXNARD G R, KLEIN E A, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA[J]. Ann Oncol, 2020, 31(6): 745-759.
27 MODING E J, NABET B Y, ALIZADEH A A, et al. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease[J]. Cancer Discov, 2021, 11(12): 2968-2986.
28 TAIEB J, TALY V, VERNEREY D, et al. Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase Ⅲ trial: prognostic and predictive value for adjuvant treatment duration[J]. Ann Oncol, 2019, 30: v867.
29 PARIKH A R, VAN SEVENTER E E, SIRAVEGNA G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer[J]. Clin Cancer Res, 2021, 27(20): 5586-5594.
30 KOJABAD A A, FARZANEHPOUR M, GALEH H E G, et al. Droplet digital PCR of viral ?DNA/RNA, current progress, challenges, and future perspectives[J]. J Med Virol, 2021, 93(7): 4182-4197.
31 COCHRAN R L, CRAVERO K, CHU D, et al. Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction[J]. Hum Pathol, 2014, 45(7): 1546-1550.
32 王童博, 李峥, 赵东兵. 胃癌腹腔分子残留病灶的诊断方法[J]. 中华胃肠外科杂志, 2023, 26(5): 419-422.
32 WANG T B, LI Z, ZHAO D B. Diagnostic methods for peritoneal molecular residual disease in gastric cancer[J]. .Chinese Journal of Gastrointestinal Surgery, 2023, 26(5): 419-422.
33 HONORé N, GALOT R, VAN MARCKE C, et al. Liquid biopsy to detect minimal residual disease: methodology and impact[J]. Cancers (Basel), 2021, 13(21): 5364.
34 KURTZ D M, SOO J, CO TING KEH L, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA[J]. Nat Biotechnol, 2021, 39(12): 1537-1547.
35 MENCEL J, SLATER S, CARTWRIGHT E, et al. The role of ctDNA in gastric cancer[J]. Cancers (Basel), 2022, 14(20): 5105.
36 ZHOU H, ZHU L, SONG J, et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer[J]. Mol Cancer, 2022, 21(1): 86.
37 TIVEY A, CHURCH M, ROTHWELL D, et al. Circulating tumour DNA: looking beyond the blood[J]. Nat Rev Clin Oncol, 2022, 19(9): 600-612.
38 LO Y M, CHAN K C, SUN H, et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus[J]. Sci Transl Med, 2010, 2(61): 61ra91.
39 TONG L, DING N, TONG X, et al. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer[J]. Theranostics, 2019, 9(19): 5532-5541.
40 TU H Y, LI Y S, BAI X Y, et al. Genetic profiling of cell-free DNA from pleural effusion in advanced lung cancer as a surrogate for tumor tissue and revealed additional clinical actionable targets[J]. Clin Lung Cancer, 2022, 23(2): 135-142.
41 VAN'T ERVE I, ROVERS K P, CONSTANTINIDES A, et al. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid[J]. J Pathol Clin Res, 2021, 7(3): 203-208.
42 HASOVITS C, CLARKE S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics[J]. Clin Pharmacokinet, 2012, 51(4): 203-224.
43 RAMALHO-CARVALHO J, HENRIQUE R, JERóNIMO C. Methylation-specific PCR[J]. Methods Mol Biol, 2018, 1708: 447-472.
44 ZENG T, HUANG Z, YU X, et al. Combining methylated SDC2 test in stool DNA, fecal immunochemical test, and tumor markers improves early detection of colorectal neoplasms[J]. Front Oncol, 2023, 13: 1166796.
45 HIRAKI M, KITAJIMA Y, SATO S, et al. Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer[J]. World J Gastroenterol, 2010, 16(3): 330-338.
46 HIRAKI M, KITAJIMA Y, KOGA Y, et al. Aberrant gene methylation is a biomarker for the detection of cancer cells in peritoneal wash samples from advanced gastric cancer patients[J]. Ann Surg Oncol, 2011, 18(10): 3013-3019.
47 YU Q M, WANG X B, LUO J, et al. CDH1 methylation in preoperative peritoneal washes is an independent prognostic factor for gastric cancer[J]. J Surg Oncol, 2012, 106(6): 765-771.
48 HAN J, LV P, YU J L, et al. Circulating methylated MINT2 promoter DNA is a potential poor prognostic factor in gastric cancer[J]. Dig Dis Sci, 2014, 59(6): 1160-1168.
49 YU J L, LV P, HAN J, et al. Methylated TIMP-3 DNA in body fluids is an independent prognostic factor for gastric cancer[J]. Arch Pathol Lab Med, 2014, 138(11): 1466-1473.
50 HU X Y, LING Z N, HONG L L, et al. Circulating methylated THBS1 DNAs as a novel marker for predicting peritoneal dissemination in gastric cancer[J]. J Clin Lab Anal, 2021, 35(9): e23936.
51 ZHAO D, YUE P, WANG T, et al. Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer[J]. J Hematol Oncol, 2021, 14(1): 164.
52 KAMIYAMA H, NODA H, TAKATA O, et al. Promoter hypermethylation of tumor-related genes in peritoneal lavage and the prognosis of patients with colorectal cancer[J]. J Surg Oncol, 2009, 100(1): 69-74.
53 LU F, DU G, ZHENG S, et al. Detection of CDH1 gene methylation of suspension cells in abdominal lavage fluid from colorectal cancer patients and its clinical significance[J]. Zhonghua Wei Chang Wai Ke Za Zhi, 2014, 17(11): 1133-1136.
54 YUAN Z, CHEN W, LIU D, et al. Peritoneal cell-free DNA as a sensitive biomarker for detection of peritoneal metastasis in colorectal cancer: a prospective diagnostic study: a prospective diagnostic study[J]. Clin Epigenetics, 2023, 15(1): 65.
55 LEICK K M, KAZARIAN A G, RAJPUT M, et al. Peritoneal cell-free tumor DNA as biomarker for peritoneal surface malignancies[J]. Ann Surg Oncol, 2020, 27(13): 5065-5071.
56 LóPEZ-ROJO I, OLMEDILLAS-LóPEZ S, VILLAREJO CAMPOS P, et al. Liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy[J]. Ther Adv Med Oncol, 2020, 12: 1758835920981351.
57 中国抗癌协会肿瘤标志专业委员会. ctDNA高通量测序临床实践专家共识(2022年版)[J]. 中国癌症防治杂志, 2022, 14(3): 240-252.
57 Tumor Marker Committee of Chinese Anti-Cancer Association. Expert consensus on clinical practice of ctDNA next generation sequencing (2022 edition)[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(3): 240-252.
Options
文章导航

/

〈 〉